Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117253) titled 'Observational study on post-marketing safety of Batroxobin injection in patients with acute cerebral infarction (acute ischemic stroke)' on Jan. 21.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Beijing Friendship Hospital, Capital Medical University
Condition:
acute cerebral infarction (acute ischemic stroke)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-02-01
Target Sample Size: Batroxobin group:600;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=305638
Disclaimer: Curated by HT Syndication....